Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (CGEM): 9 pipeline candidates · ~22 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
22.2 months
0% dilution
Lead: Phase 3
9 candidates
N/A
0 buys · 18 sells (180d)
A transparent, data-derived signal for Cullinan Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$826.0M
Cash
$75.1M
Quarterly Burn
$46.0M
Runway
22.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| CLN-049 | Phase 1 |
| CLN-418 | Phase 1 |
| CLN-617 | Phase 1 |
| CLN-619 | Phase 1 |
| CLN-978 | Phase 1 |
| Novel HPK1 degraders (discovery collaboration) | Preclinical |
| velinotamig | Phase 1 |
| zipalertinib | Phase 3 |
| Zipalertinib (CLN-081/TAS6417) | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
171
Total value held
$867.3M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 8,963,500 | $127.4M |
| mpm bioimpact llc | 7,648,268 | $108.7M |
| bvf inc/il | 5,750,683 | $81.7M |
| vanguard capital management llc | 4,966,068 | $70.6M |
| blackrock, inc. | 4,449,966 | $63.2M |
| state street corp | 2,544,115 | $36.2M |
| rtw investments, lp | 1,705,960 | $24.2M |
| venrock adviser, llc | 1,379,965 | $19.6M |
| geode capital management, llc | 1,368,268 | $19.4M |
| siren, l.l.c. | 1,193,410 | $17.0M |
Showing top 10 of 171 institutional holders of Cullinan Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cullinan Therapeutics, Inc.'s pipeline?
Cullinan Therapeutics, Inc. (CGEM) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cullinan Therapeutics, Inc.'s lead drug candidate?
Cullinan Therapeutics, Inc.'s most advanced tracked candidate is CLN-049 (Phase 1) for Relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
What is Cullinan Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cullinan Therapeutics, Inc. has approximately 22.2 months of cash runway.
What is Cullinan Therapeutics, Inc.'s market capitalization?
Cullinan Therapeutics, Inc.'s market capitalization is approximately $826.0M.
Who is the CEO of Cullinan Therapeutics, Inc.?
Mr. Nadim Ahmed M.S. is the chief executive officer of Cullinan Therapeutics, Inc. (CGEM).
Get the full picture on Cullinan Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.